$RGEN
REPLIGEN CORP

2017 Q4 Form 10-K Financial Statement

#000119312518054262 Filed on February 22, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $41.61M $36.58M $32.46M
YoY Change 62.54% 48.24% 11.26%
Cost Of Revenue $19.14M $19.99M $13.94M
YoY Change 57.34% 77.79% 10.23%
Gross Profit $22.48M $16.59M $18.52M
YoY Change 67.25% 23.51% 12.05%
Gross Profit Margin 54.01% 45.36% 57.06%
Selling, General & Admin $16.14M $15.00M $11.19M
YoY Change 88.42% 110.44% 37.41%
% of Gross Profit 71.83% 90.39% 60.4%
Research & Development $3.069M $2.001M $1.860M
YoY Change 50.44% 6.1% -1.59%
% of Gross Profit 13.66% 12.06% 10.04%
Depreciation & Amortization $4.140M $3.090M $1.700M
YoY Change 177.85% 125.55% 28.79%
% of Gross Profit 18.42% 18.62% 9.18%
Operating Expenses $38.35M $36.99M $26.98M
YoY Change 261.51% 310.36% 169.01%
Operating Profit $3.262M -$406.0K $5.473M
YoY Change 12.29% -110.84% -6.59%
Interest Expense $1.637M $1.618M $1.601M
YoY Change 4.27% 4.05% 150.94%
% of Operating Profit 50.18% 29.25%
Other Income/Expense, Net -$139.0K -$1.616M -$328.0K
YoY Change -216.81% 2054.67% -537.33%
Pretax Income $1.549M -$2.022M $3.654M
YoY Change -1.09% -191.33% -31.98%
Income Tax -$10.63M -$6.691M -$4.784M
% Of Pretax Income -686.18% -130.93%
Net Earnings $12.18M $4.669M $8.438M
YoY Change 142.16% 304.24% 117.92%
Net Earnings / Revenue 29.27% 12.76% 26.0%
Basic Earnings Per Share $0.28 $0.11 $0.25
Diluted Earnings Per Share $0.27 $0.11 $0.24
COMMON SHARES
Basic Shares Outstanding 43.57M shares 41.24M shares 34.10M shares
Diluted Shares Outstanding 44.39M shares 42.56M shares 35.09M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $173.8M $159.7M $145.0M
YoY Change 22.57% -10.63% -20.24%
Cash & Equivalents $173.8M $159.7M $142.2M
Short-Term Investments $0.00 $0.00 $2.700M
Other Short-Term Assets $218.0K $2.800M $2.300M
YoY Change 207.04% 115.38% 76.92%
Inventory $39.00M $38.66M $26.09M
Prepaid Expenses
Receivables $27.59M $29.48M $22.12M
Other Receivables $100.0K $600.0K $500.0K
Total Short-Term Assets $242.8M $231.2M $195.9M
YoY Change 31.84% 5.17% -10.09%
LONG-TERM ASSETS
Property, Plant & Equipment $22.42M $22.06M $16.00M
YoY Change 49.89% 47.68% 16.7%
Goodwill $327.3M $326.7M $60.98M
YoY Change 449.7% 948.27% 96.54%
Intangibles $144.8M $147.4M $29.01M
YoY Change 385.65% 689.55% 51.22%
Long-Term Investments
YoY Change
Other Assets $6.234M $6.467M $6.380M
YoY Change 1146.8% 1193.4% 1176.0%
Total Long-Term Assets $500.7M $503.0M $112.8M
YoY Change 377.98% 671.33% 75.27%
TOTAL ASSETS
Total Short-Term Assets $242.8M $231.2M $195.9M
Total Long-Term Assets $500.7M $503.0M $112.8M
Total Assets $743.5M $734.2M $308.8M
YoY Change 157.35% 157.58% 9.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.282M $6.423M $6.951M
YoY Change 43.88% 26.91% -9.59%
Accrued Expenses $17.93M $13.79M $9.568M
YoY Change 11.96% -8.84% -29.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $98.20M
YoY Change
Total Short-Term Liabilities $25.21M $118.4M $16.52M
YoY Change 19.63% 486.6% -22.63%
LONG-TERM LIABILITIES
Long-Term Debt $99.30M $0.00 $97.20M
YoY Change 4.2% -100.0% 4.07%
Other Long-Term Liabilities $2.343M $1.573M $1.616M
YoY Change 37.9% -16.95% -13.95%
Total Long-Term Liabilities $2.343M $1.573M $1.616M
YoY Change 37.9% -16.95% -13.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.21M $118.4M $16.52M
Total Long-Term Liabilities $2.343M $1.573M $1.616M
Total Liabilities $152.0M $120.0M $18.14M
YoY Change 567.3% 443.42% -21.93%
SHAREHOLDERS EQUITY
Retained Earnings -$31.51M -$43.69M -$48.36M
YoY Change -47.36% -32.68% -26.79%
Common Stock $629.4M $627.2M $248.0M
YoY Change 159.69% 160.35% 3.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $591.5M $576.9M $190.9M
YoY Change
Total Liabilities & Shareholders Equity $743.5M $734.2M $308.8M
YoY Change 157.35% 157.58% 9.37%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income $12.18M $4.669M $8.438M
YoY Change 142.16% 304.24% 117.92%
Depreciation, Depletion And Amortization $4.140M $3.090M $1.700M
YoY Change 177.85% 125.55% 28.79%
Cash From Operating Activities $15.22M -$1.730M $2.810M
YoY Change 680.51% 46.61% -73.39%
INVESTING ACTIVITIES
Capital Expenditures -$1.760M -$1.010M -$1.380M
YoY Change 102.3% -50.73% 40.82%
Acquisitions
YoY Change
Other Investing Activities $150.0K -$110.2M $9.440M
YoY Change -100.44% 829.96% -4820.0%
Cash From Investing Activities -$1.620M -$111.2M $8.050M
YoY Change -95.41% 700.07% -782.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.3M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.0K 129.8M 160.0K
YoY Change -444.44% 30807.14% -99.86%
NET CHANGE
Cash From Operating Activities 15.22M -1.730M 2.810M
Cash From Investing Activities -1.620M -111.2M 8.050M
Cash From Financing Activities 310.0K 129.8M 160.0K
Net Change In Cash 13.91M 16.87M 11.02M
YoY Change -141.58% -215.08% -90.88%
FREE CASH FLOW
Cash From Operating Activities $15.22M -$1.730M $2.810M
Capital Expenditures -$1.760M -$1.010M -$1.380M
Free Cash Flow $16.98M -$720.0K $4.190M
YoY Change 502.13% -182.76% -63.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43588469 shares
CY2011Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2807017 shares
CY2017Q3 rgen Common Stock Issue Price Per Share
CommonStockIssuePricePerShare
42.75
CY2017Q2 dei Entity Public Float
EntityPublicFloat
1225041904
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
111732000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35363000
CY2015Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
1899000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
122748000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54092000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33844074 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33844074 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
882748 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.88
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59861000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1699000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
288913000
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
435000
CY2016Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
5841000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
23000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5586000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
408000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13394000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13749000
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
1792000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5061000
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
382000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
168764000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2103000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
338000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
242036000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19332000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
411000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1407000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6695000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2103000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
952000
CY2016Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
3662000
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1692000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1168000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21075000
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6119000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9979000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
7346000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
95272000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6119000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
248000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16014000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
184153000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
3333000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2789000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
71000
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
356000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14956000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
450000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
19547000
CY2016Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
183000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122233000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12284000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2036000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29806000
CY2016Q4 us-gaap Inventory Net
InventoryNet
24696000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15194000
CY2016Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
104760000
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1264000
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
5000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1722000
CY2016Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
3218000
CY2016Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
15214000
CY2016Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
839000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
34288000
CY2016Q4 us-gaap Assets
Assets
288913000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2016Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
19829000
CY2016Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
1267000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21270000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11291000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1895000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
6950000
CY2016Q4 us-gaap Goodwill
Goodwill
59548000
CY2016Q4 us-gaap Goodwill Gross
GoodwillGross
46505000
CY2016Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
36501000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6953000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14954000
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
14592000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1644000
CY2016Q4 us-gaap Prepaid Taxes
PrepaidTaxes
626000
CY2016Q4 rgen Business Combination Considerations Transferred Net
BusinessCombinationConsiderationsTransferredNet
45566000
CY2016Q4 rgen Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
1420000
CY2016Q4 rgen Prepaid Services And Professional Fees
PrepaidServicesAndProfessionalFees
586000
CY2016Q4 rgen Deferred Tax Liabilities Conversion Option On Convertible Notes
DeferredTaxLiabilitiesConversionOptionOnConvertibleNotes
6048000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.71
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43587079 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
727278 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1220915 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43587079 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
420688 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.86
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
734940 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.80
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Share Price
SharePrice
36.28
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1806000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31508000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2343000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
15071000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3383000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
743519000
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
455000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9560000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
960000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
36349000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6363000
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
1656000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7282000
CY2017Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1191000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
591548000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2750000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3611000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1464000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
25167000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
436000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
628983000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23800000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
947000
CY2017Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
53747000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1806000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3077000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13331000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
25167000
CY2017Q4 us-gaap Contractual Obligation
ContractualObligation
15512000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
7698000
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
43608000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
58000
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1668000
CY2017Q4 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
0
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2220000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
144753000
CY2017Q4 us-gaap Inventory Net
InventoryNet
39004000
CY2017Q4 us-gaap Land
Land
1023000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
786000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25211000
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
33166000
CY2017Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
99250000
CY2017Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1383000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17929000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
242782000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
2196000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4083000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
218000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
594000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22417000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8720000
CY2017Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
764000
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
1718000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173759000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4361000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1265000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16133000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
10633000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
9376000
CY2017Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11472000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27585000
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
500737000
CY2017Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2581000
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
67000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1662000
CY2017Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
4272000
CY2017Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
21904000
CY2017Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
153000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46217000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2017Q4 us-gaap Assets
Assets
743519000
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
120080000
CY2017Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
5075000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11188000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11182000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1704000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
5562000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
9374000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9894000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
10578000
CY2017Q4 us-gaap Goodwill
Goodwill
327333000
CY2017Q4 us-gaap Goodwill Gross
GoodwillGross
265519000
CY2017Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
158084000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12570000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
22351000
CY2017Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
15673000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6234000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2281000
CY2017Q4 us-gaap Prepaid Taxes
PrepaidTaxes
311000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11558000
CY2017Q4 rgen Business Combination Considerations Transferred Net
BusinessCombinationConsiderationsTransferredNet
113220000
CY2017Q4 rgen Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
19709000
CY2017Q4 rgen Sharebased Compensation Arrangement By Sharebased Payment Award Options And Equity Instruments Other Than Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedNumberOfShares
772791 shares
CY2017Q4 rgen Prepaid Services And Professional Fees
PrepaidServicesAndProfessionalFees
1091000
CY2017Q4 rgen Deferred Tax Liabilities Conversion Option On Convertible Notes
DeferredTaxLiabilitiesConversionOptionOnConvertibleNotes
3183000
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129309000
CY2014Q1 rgen Lease Commencement Date
LeaseCommencementDate
2014-08-01
CY2014Q1 rgen Lease Agreement Term
LeaseAgreementTerm
P8Y1M
CY2011Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-05-31
CY2011Q3 rgen Lease Agreement Area
LeaseAgreementArea
55694 sqft
CY2011Q3 rgen Lease Agreement Term
LeaseAgreementTerm
P11Y
CY2001 rgen Lease Agreement Area
LeaseAgreementArea
25000 sqft
CY2001 rgen Lease Agreement Term
LeaseAgreementTerm
P10Y
CY2007 rgen Lease Agreement Area
LeaseAgreementArea
2500 sqft
CY2007 rgen Lease Agreement Term
LeaseAgreementTerm
P5Y
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
196209 shares
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.091 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.026 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
15053000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5189 pure
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33577091 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32881940 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.017 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5009 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0167 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.05
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.142 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.027 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.009 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0203 pure
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.304 pure
CY2015 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
695151 shares
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1216000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1536000
CY2015 us-gaap Revenues
Revenues
83537000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2628000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
136000
CY2015 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
115000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
866000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
83537000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20168000
CY2015 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
99000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
13764000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
9345000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6149000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3729000
CY2015 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6552000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3598000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2815000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
4948000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-445000
CY2015 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-158000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
277000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
15913000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2490000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13423000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4083000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-118000
CY2015 us-gaap Depreciation
Depreciation
2996000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1882000
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
295000
CY2015 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
3507000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4078000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3024000
CY2015 us-gaap Interest Expense
InterestExpense
32000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4791000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
3598000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3745000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4594000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
4564000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-230000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
348000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2115000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24699000
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
276000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
69773000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1592000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
767000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2619000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5740000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3638000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18729000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
35251000
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1910000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-358000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
563000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1216000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
27587000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
866000
CY2015 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
333000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
317923 shares
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1.678 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.131 pure
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0000730272
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2017 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P16Y
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Organization and Nature of Business</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the interconnected phases of the biological drug manufacturing process. The Company&#x2019;s portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS <font style="white-space:nowrap">pre-packed</font> columns, chromatography resins, ELISA kits), and filtration products (XCell ATF Systems, Sius TFF cassettes, KrosFlo filters, modules and systems). The Company&#x2019;s bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Protein A ligands and growth factor products that the Company manufactures are components of chromatography resins and cell culture media, respectively.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company is the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. The Company&#x2019;s growth factors are used in upstream processes to accelerate cell growth and productivity in a bioreactor. The Company&#x2019;s innovative line of OPUS chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered <font style="white-space:nowrap">pre-packed</font> with its customers&#x2019; choice of resin and volume. The Company&#x2019;s XCell ATF Systems, available in stainless steel and <font style="white-space:nowrap">single-use</font> configurations, continuously eliminate waste from a bioreactor, to accelerate and increase productivity in upstream processes. <font style="white-space:nowrap">Single-use</font> Sius TFF cassettes and hardware are used for biologic drug concentration in downstream processes. KrosFlo filters and systems are used in the filtration, isolation, purification and concentration of biologics. Repligen&#x2019;s corporate headquarters are in Waltham, Massachusetts (USA) and its manufacturing facilities are located in Waltham, Massachusetts; Shrewsbury, Massachusetts; Rancho Dominguez, California; Las Vegas, Nevada; Houston, Texas; Irving, Texas; Lund, Sweden; and Weingarten, Germany.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company&#x2019;s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the FDA and other governmental regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business and obtain adequate funding to finance this growth.</p> </div>
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
17451000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
34157 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M16D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.92
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2017 dei Trading Symbol
TradingSymbol
RGEN
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39150374 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38233527 shares
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk and Significant Customers</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company&#x2019;s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December&#xA0;31, 2017 and 2016, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential <font style="WHITE-SPACE: nowrap">write-off</font> of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers&#x2019; financial condition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Revenue from significant customers as a percentage of the Company&#x2019;s total revenue is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"> <b>Years&#xA0;ended&#xA0;December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> GE Healthcare</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MilliporeSigma</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Significant accounts receivable balances as a percentage of the Company&#x2019;s total trade accounts receivable and royalties and other receivable balances are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="22%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="21%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> GE Healthcare</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MilliporeSigma</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> </div>
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.064 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.042 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.38
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0188 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M11D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.94
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.772 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.248 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.021 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.098 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0199 pure
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
215495 shares
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Significant estimates and assumptions by management affect the Company&#x2019;s revenue recognition for multiple element arrangements, allowance for doubtful accounts, the net realizable value of inventory, estimated fair value of cost method investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, fair value estimates of contingent consideration, contingent liabilities, tax reserves and recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p> </div>
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-2.912 pure
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M7D
CY2017 dei Entity Registrant Name
EntityRegistrantName
REPLIGEN CORP
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
474923 shares
CY2017 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-31
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2017 us-gaap Revenues
Revenues
141236000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5454000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-9973000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2220000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y5M9D
CY2017 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
441924 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5148 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
20.23
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
101844 shares
CY2017 us-gaap Investment Income Net
InvestmentIncomeNet
371000
CY2017 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
7708000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2351000
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
141089000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
47000
CY2017 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
1715000
CY2017 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
112795000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
14005000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-605000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
28353000
CY2017 us-gaap Interest Paid
InterestPaid
2444000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6888000
CY2017 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
35739000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6747000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
199000
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
247575000
CY2017 us-gaap Royalty Revenue
RoyaltyRevenue
147000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7381000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
4021000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
679000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129309000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-687000
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-644000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1304000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
13957000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-6709000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7248000
CY2017 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-64000
CY2017 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
247575000
CY2017 us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
450000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-24679000
CY2017 us-gaap Depreciation
Depreciation
4237000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2376000
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-24012000
CY2017 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
3345000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-12839000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-21105000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
807000
CY2017 us-gaap Interest Expense
InterestExpense
6441000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-98246000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129309000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
6747000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3977000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3624000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10507000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2537000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
470000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-946000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
611000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51509000
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-438000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8691000000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
127231000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1993000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129945000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3367000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8672000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5305000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6215000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
51526000
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
67050000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
6119000
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1797000
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-151000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-307000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-12164000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19600000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2351000
CY2017 rgen Lease Agreement Area
LeaseAgreementArea
45000 sqft
CY2017 rgen Business Acquisition Working Capital Adjustments
BusinessAcquisitionWorkingCapitalAdjustments
425000
CY2017 rgen Lease Agreement Termination Description
LeaseAgreementTerminationDescription
The Company terminated the lease on the 7,350 square feet of space in the first quarter of 2015.
CY2017 rgen Income Tax Reconciliation Transaction Costs
IncomeTaxReconciliationTransactionCosts
1232000
CY2017 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
-24729000
CY2017 rgen Stock Issued During Period Value Contingent Considerations
StockIssuedDuringPeriodValueContingentConsiderations
1063000
CY2017 rgen Number Of Buildings Leased
NumberOfBuildingsLeased
4 Building
CY2017 rgen Effective Income Tax Rate Reconciliation Transaction Cost
EffectiveIncomeTaxRateReconciliationTransactionCost
0.170 pure
CY2017 rgen Payment Of Contingent Consideration In Common Stock
PaymentOfContingentConsiderationInCommonStock
1063000
CY2017 rgen Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit
12812000
CY2017 rgen Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense
3266000
CY2017 rgen Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTax
0.451 pure
CY2017 rgen Unrecognized Tax Benefits Period Gross Decreases Release
UnrecognizedTaxBenefitsPeriodGrossDecreasesRelease
479000
CY2008 rgen Lease Agreement Area
LeaseAgreementArea
7350 sqft
CY2008 rgen Lease Agreement Term
LeaseAgreementTerm
P2Y
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
381686 shares
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.169 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.003 pure
CY2016 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
7521000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5101 pure
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34098898 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33572883 shares
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.032 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.028 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5085 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0151 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.16
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.174 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.020 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0237 pure
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001 pure
CY2016 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
526015 shares
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-8535000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1713000
CY2016 us-gaap Revenues
Revenues
104541000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4325000
CY2016 us-gaap Investment Income Net
InvestmentIncomeNet
346000
CY2016 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
236000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15000
CY2016 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
18072000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1841000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
104441000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23700000
CY2016 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
798000
CY2016 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
44614000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
15974000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
11681000
CY2016 us-gaap Interest Paid
InterestPaid
1222000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6163000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3222000
CY2016 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6498000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4595000
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14135000
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
100000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5189000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
3993000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-860000
CY2016 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
652000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-612000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
16574000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-4882000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11692000
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-7000
CY2016 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
14135000
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3242000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4092000
CY2016 us-gaap Depreciation
Depreciation
3269000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2299000
CY2016 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-3809000
CY2016 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
4027000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1802000
CY2016 us-gaap Interest Expense
InterestExpense
3768000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-49194000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
4595000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2274000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4077000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5334000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3975000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
380000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
31000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-240000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
111070000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30853000
CY2016 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-207000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
639000000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
88567000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4038000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
112113000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2644000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7355000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5043000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2052000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
68141000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
47117000
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-2031000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
43000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-326000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1981000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
23400000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1841000
CY2016 rgen Income Tax Reconciliation Transaction Costs
IncomeTaxReconciliationTransactionCosts
156000
CY2016 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
-4066000
CY2016 rgen Stock Issued During Period Value Contingent Considerations
StockIssuedDuringPeriodValueContingentConsiderations
875000
CY2016 rgen Long Term Marketable Securities Maturities Term Minimum
LongTermMarketableSecuritiesMaturitiesTermMinimum
P1Y
CY2016 rgen Effective Income Tax Rate Reconciliation Transaction Cost
EffectiveIncomeTaxRateReconciliationTransactionCost
0.013 pure
CY2016 rgen Payment Of Contingent Consideration In Common Stock
PaymentOfContingentConsiderationInCommonStock
875000
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34382000 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33892000 shares
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2017Q1 us-gaap Revenues
Revenues
30590000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
96000
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
30569000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
5676000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
3068000
CY2017Q1 us-gaap Royalty Revenue
RoyaltyRevenue
21000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4067000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
999000
CY2017Q1 us-gaap Interest Expense
InterestExpense
1585000
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9182000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
24914000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1742000
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
13990000
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33494000 shares
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33025000 shares
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2016Q1 us-gaap Revenues
Revenues
25094000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
61000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25094000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
3463000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
1625000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-979000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2540000
CY2016Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2005000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
915000
CY2016Q1 us-gaap Interest Expense
InterestExpense
5000
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7018000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
21631000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1539000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11069000
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34175000 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33649000 shares
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2016Q2 us-gaap Revenues
Revenues
29170000
CY2016Q2 us-gaap Investment Income Net
InvestmentIncomeNet
76000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
29170000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
5859000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
3872000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
75000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5372000
CY2016Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
637000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1500000
CY2016Q2 us-gaap Interest Expense
InterestExpense
638000
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8140000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
23311000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1890000
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12644000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35095000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34098000 shares
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2017Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-9200000
CY2017Q2 us-gaap Revenues
Revenues
32455000
CY2017Q2 us-gaap Investment Income Net
InvestmentIncomeNet
110000
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
32434000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
5473000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
8438000
CY2017Q2 us-gaap Royalty Revenue
RoyaltyRevenue
21000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-328000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3654000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4784000
CY2017Q2 us-gaap Interest Expense
InterestExpense
1601000
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11185000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
26982000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1860000
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
13937000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34313000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33779000 shares
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2016Q3 us-gaap Revenues
Revenues
24677000
CY2016Q3 us-gaap Investment Income Net
InvestmentIncomeNet
97000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
24677000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3747000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
1155000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-75000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2214000
CY2016Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
675000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1059000
CY2016Q3 us-gaap Interest Expense
InterestExpense
1555000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7127000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
20930000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1886000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11242000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42563000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41237000 shares
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2017Q3 us-gaap Revenues
Revenues
36580000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
102000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
36514000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-406000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
4669000
CY2017Q3 us-gaap Royalty Revenue
RoyaltyRevenue
66000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2022000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6691000
CY2017Q3 us-gaap Interest Expense
InterestExpense
1618000
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14998000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
36986000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2001000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
19987000
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34369000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33833000 shares
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2016Q4 us-gaap Revenues
Revenues
25600000
CY2016Q4 us-gaap Investment Income Net
InvestmentIncomeNet
112000
CY2016Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25500000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
2905000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
5029000
CY2016Q4 us-gaap Royalty Revenue
RoyaltyRevenue
100000
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
119000
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1566000
CY2016Q4 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-75000
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3463000
CY2016Q4 us-gaap Interest Expense
InterestExpense
1570000
CY2016Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8568000
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
22695000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2040000
CY2016Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12162000
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44385000 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43569000 shares
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2017Q4 us-gaap Revenues
Revenues
41611000
CY2017Q4 us-gaap Investment Income Net
InvestmentIncomeNet
63000
CY2017Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
41572000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
3262000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
12178000
CY2017Q4 us-gaap Royalty Revenue
RoyaltyRevenue
39000
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-139000
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1549000
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10629000
CY2017Q4 us-gaap Interest Expense
InterestExpense
1637000
CY2017Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16144000
CY2017Q4 us-gaap Costs And Expenses
CostsAndExpenses
38349000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3069000
CY2017Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
19136000

Files In Submission

Name View Source Status
0001193125-18-054262-index-headers.html Edgar Link pending
0001193125-18-054262-index.html Edgar Link pending
0001193125-18-054262.txt Edgar Link pending
0001193125-18-054262-xbrl.zip Edgar Link pending
d516591d10k.htm Edgar Link pending
d516591dex211.htm Edgar Link pending
d516591dex231.htm Edgar Link pending
d516591dex311.htm Edgar Link pending
d516591dex312.htm Edgar Link pending
d516591dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g516591g67u99.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgen-20171231.xml Edgar Link completed
rgen-20171231.xsd Edgar Link pending
rgen-20171231_cal.xml Edgar Link unprocessable
rgen-20171231_def.xml Edgar Link unprocessable
rgen-20171231_lab.xml Edgar Link unprocessable
rgen-20171231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending